What are analysts'price targets for GATX stock?
4 analysts have issued twelve-month price targets for GATX's stock. Their forecasts range from $89.97 to $120.00. On average, they expect GATX's share price to reach $103.66 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price.
Who owns GATX stock?
Company insiders that own GATX stock include Amita Shetty, Brian A Kenney, Deborah A Golden, James M Conniff, Jeffery R Young, Necati Gokce Tezel, Niyi Adedoyin, Paul F Titterton, Robert C Lyons, Robert Zmudka and Thomas A Ellman. View institutional ownership trends for GATX.
Does GATX have an upside of 8% from current price?
According to analysts' consensus price target of $103.66, GATX has a forecasted upside of 8.8% from its current price of $95.24. GATX has only been the subject of 1 research reports in the past 90 days. GATX has received 318 “outperform” votes. (Add your “outperform” vote.) GATX has received 204 “underperform” votes. (Add your “underperform” vote.)
Is Direxion Daily Natural Gas Related Bear 3X Shares a good dividend stock?
Direxion Daily Natural Gas Related Bear 3X Shares pays an annual dividend of $0.20 per share and currently has a dividend yield of 1.53%. View Dir...
When did Direxion Daily Natural Gas Related Bear 3X Shares' stock split? How did Direxion Daily Natural Gas Related Bear 3X Shares' stock split work?
Shares of Direxion Daily Natural Gas Related Bear 3X Shares split before market open on Friday, March 27th 2020. The 10-1 split was announced on Fr...
Who are some of Direxion Daily Natural Gas Related Bear 3X Shares' key competitors?
Some companies that are related to Direxion Daily Natural Gas Related Bear 3X Shares include Cushing 30 MLP Index ETN (PPLN) , iShares iBonds Mar...
What other stocks do shareholders of Direxion Daily Natural Gas Related Bear 3X Shares own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Direxion Daily Natural Gas Related Bear 3X Shares investors...
What is Direxion Daily Natural Gas Related Bear 3X Shares' stock symbol?
Direxion Daily Natural Gas Related Bear 3X Shares trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "GASX."
How do I buy shares of Direxion Daily Natural Gas Related Bear 3X Shares?
Shares of GASX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Direxion Daily Natural Gas Related Bear 3X Shares' stock price today?
One share of GASX stock can currently be purchased for approximately $16.00.
How much money does Direxion Daily Natural Gas Related Bear 3X Shares make?
Direxion Daily Natural Gas Related Bear 3X Shares has a market capitalization of $19.98 million.
Ideas
Profile
columbia natty play, huge revenues ahead once all hooked up, +1 MILL /DAY cash flow, bustin out on volume even tho natty dived
About GATX
NG Energy International Corp. engages in the exploration, acquisition, evaluation, development, and production of oil and gas. It holds interest in Maria Conchita block, Sinu-9 block, and Tiburon block. The company was founded on March 6, 1998 and is headquartered in Vancouver, Canada.
Headlines
GATX Corp. engages in leasing and owning railcar and fleets in North America, Europe and Asia. It operates through the following segments: Rail North America, Rail International and Portfolio Management.
GATX (NYSE:GATX) Frequently Asked Questions
What's in the Offing for Genco Shipping (GNK) in Q4 Earnings? - Nasdaq
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GATX in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GATX stock. View analyst ratings for GATX or view top-rated stocks.
Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day
Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functionsBETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc.
